Up­dat­ed: Virid­i­an re­veals first Phase 3 eye dis­ease da­ta in bid to com­pete with Te­pez­za

Virid­i­an Ther­a­peu­tics on Tues­day re­port­ed topline Phase 3 da­ta for its rare au­toim­mune dis­ease drug veli­gro­tug as it aims to com­pete with Am­gen and Hori­zon …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER